Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | HTR6 known ✓ | P50406 | 4/20 | 0.44 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.44 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.44 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.44 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MOGAT2 | Q3SYC2 | 2/20 | 0.47 |
| ▸ | MLNR | O43193 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.41 |
| ▸ | KCNT2 | Q6UVM3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2485303 | 0.86 | MLNR (0.48) | MOGAT2MLNRHTR6DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL1959549 | 0.86 | EPHX2 (0.55) | EPHX2MOGAT2HRH3MLNRHTR6 | |
| Hydrochloric Acid SCHEMBL1959733 | 0.83 | DRD2 (0.52) | EPHX2MOGAT2MLNRHTR6DRD2 | |
| Hydrochloric Acid SCHEMBL1961829 | 0.83 | EPHX2 (0.65) | EPHX2MOGAT2HRH3MLNRHTR6 | |
| Hydrochloric Acid SCHEMBL1960382 | 0.82 | DRD2 (0.61) | EPHX2MOGAT2MLNRHTR6DRD2 | |
| Hydrochloric Acid SCHEMBL1960292 | 0.82 | DRD2 (0.51) | EPHX2MOGAT2HRH3MLNRHTR6 | |
| Hydrochloric Acid SCHEMBL1958519 | 0.82 | DRD2 (0.50) | EPHX2MOGAT2MLNRHTR6DRD2 | |
| SCHEMBL1959732 | 0.82 | MLNR (0.53) | MOGAT2HRH3MLNRHTR6DRD2 | |
| SCHEMBL1959952 | 0.81 | DRD2 (0.52) | EPHX2MOGAT2MLNRHTR6DRD2 | |
| Hydrochloric Acid SCHEMBL1957424 | 0.81 | HTR6 (0.51) | EPHX2MOGAT2MLNRHTR6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846830-B2 | Naphtalene derivatives and their pharmaceutical use | ELI LILLY AND COMPANY (US) | 2005-01-25 | — | — | US | claimed |
| US-20030073725-A1 | Naphtalene derivatives and their pharmaceutical use | ELI LILLY AND COMPANY | 2003-04-17 | — | — | US | claimed |
| EP-1138328-A1 | Naphthalene derivatives as CNS drugs | ELI LILLY AND COMPANY LIMITED (GB) | 2001-10-04 | — | — | EP | claimed |
| US-8207160-B2 | Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-1694334-B1 | TETRAHYDROBENZAZEPINES AND THEIR USE IN THE MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-10-19 | — | — | EP | disclosed |
| US-20090105224-A1 | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20050137186-A1 | Tetrahydrobenzazepines and their use | ABBOTT GMBH & CO. KG. | 2005-06-23 | — | — | US | disclosed |
| US-6846830-B2 | Naphtalene derivatives and their pharmaceutical use | ELI LILLY AND COMPANY (US) | 2005-01-25 | — | — | US | disclosed |
| US-20030073725-A1 | Naphtalene derivatives and their pharmaceutical use | ELI LILLY AND COMPANY | 2003-04-17 | — | — | US | disclosed |
| EP-1138328-A1 | Naphthalene derivatives as CNS drugs | ELI LILLY AND COMPANY LIMITED (GB) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137186-A1 | Tetrahydrobenzazepines and their use | DRD3, ADRB3, AVPR1B | HRH3 333/4885HTR6 115/4885DRD2 9/4885 |
| US-20090105224-A1 | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor | DRD3, DRD2, ADRB3 | HRH3 218/4885HTR6 124/4885DRD2 2/4885 |
| US-20030073725-A1 | Naphtalene derivatives and their pharmaceutical use | CHRNA6, ATP6V1B2, GRM6 | HRH3 594/4885HTR6 91/4885DRD2 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.